Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro.

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Abstract Text:

Akira Nakamura,Chi Ly,Mirijana Cipeti?,Natalie A Sims,Jessica Vieusseux,Vicky Kartsogiannis,Stelios Bouralexis,Hasnawati Saleh,Hong Zhou,John T Price,T John Martin,Kong Wah Ng,Matthew T Gillespie,Julian M W Quinn,

Osteoclast inhibitory lectin (OCIL) is a type II C-type lectin and binds NK cell-associated receptor Nkrp1d and sulfated glycosaminoglycans. OCIL is expressed by several cell types found in bone and inhibits osteoclast differentiation. To determine whether OCIL may have wider effects on bone metabolism, we examined the effects of recombinant soluble OCIL on cultured osteoblasts and pre-osteoblastic KUSA O cells. Although OCIL did not affect osteoblast proliferation or apoptosis, or the formation of alkaline phosphatase positive colonies in cultured bone marrow, OCIL profoundly inhibited mineralization by primary osteoblasts and KUSA O cells in vitro. Analysis of ascorbate-treated KUSA O cells showed that addition of OCIL reduced bone sialoprotein (BSP), osterix and osteocalcin mRNA expression, as well as alkaline phosphatase activity while, in contrast, expression of markers associated with the earlier stages of osteoblast maturation or the transcription factors Runx2, ATF4 and c-fos were not affected by OCIL treatment. Indeed, osteocalcin expression was strongly inhibited within 3 days in a dose-dependent manner, although after subsequent removal of OCIL, osteocalcin mRNA levels recovered within 4 days. OCIL treatment also reduced osteocalcin expression in BMP-2 stimulated C2C12 cells. In support of a role for OCIL in mineralization, OCIL anti-sense oligonucleotide treatment of KUSA O cells increased mineralization and osteocalcin expression. In addition, insulin-, dexamethasone- and IBMX-stimulated KUSA O cells undergo adipocyte differentiation and OCIL treatment greatly suppressed this process. Consistent with this, OCIL also reduced adiponectin and resistin mRNA expression in these cells. Our data indicate that OCIL reduces osteoblastic function in vitro and this may be due to an inhibitory effect on osteoblast maturation. In addition, the reduction of adipocyte formation in KUSA O cells by OCIL indicates that OCIL may have wider effects on the mesenchymal lineage that may be important for both bone metabolism and other connective tissue functions.

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Publishing Authors By Initials

A Nakamura,C Ly,M Cipeti?,NA Sims,J Vieusseux,V Kartsogiannis,S Bouralexis,H Saleh,H Zhou,JT Price,TJ Martin,KW Ng,MT Gillespie,JM Quinn,

For similar peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research

PUBMED ID PMID:

MEDLINE DATE:

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Bone

VOLUME: 40

Page Numbers: 305-15

Journal Abbreviation: Bone

ISSN: 8756-3282

DAY: 13

MONTH: 10

YEAR: 2006

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8504048

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Keywords Mesh Terms:

KEYWORDS: Transforming Growth Factor beta

MESH TERMS: metabolism

Chemical & Substance for Abstract: Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Information

Substance Name: Osteopontin

Registry Number: 106441-73-0

Grant and Affiliation Information for Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro.

AFFILIATION: St. Vincent's Institute, 9, Princes Street, Fitzroy, Victoria, Australia.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bone

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Osteoclast inhibitory lectin OCIL inhibits osteoblast differentiation and function in vitro Related Publications

• A role for eyebrows in regulating the visibility of eye gaze direction.
• Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging.
• Comments on the analysis of some triacid triglyceride mixtures.
• Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.
• Contact Lenses in Pediatrics (CLIP) Study: chair time and ocular health.
• Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm.
• Gender and cleaner production: toward a framework for including gender analysis when developing strategies and designing solutions.
• Generation of a transgenic model to address regulation and function of the human neurokinin 1 receptor (NK1R).
• High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.
• Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
• Infants' sensitivity to uniform connectedness as a cue for perceptual organization.
• Melanoma imaging with pretargeted bivalent bacteriophage.
• N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase.
• Nitric oxide-NGF mediated PPTA/SP, ADNP, and VIP expression in the peripheral nervous system.
• Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro.
• Passivating protein coatings for implantable glucose sensors: evaluation of protein retention.
• Pharmacological treatment of heart failure.
• Reducing health disparities in depressive disorders outcomes between non-Hispanic Whites and ethnic minorities: a call for pragmatic strategies over the life course.
• Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
• Retinopathy of prematurity in Brazil: an emerging problem.
• Review: advance provision of emergency contraception increases its use but does not reduce unplanned pregnancies.
• Role of NF-kappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha.
• Spina bifida advocacy--a case study in public policy success.
• Systemic reaction rates to field stings among imported fire ant-sensitive patients receiving >3 years of immunotherapy versus <3 years of immunotherapy.
• The future in advanced prostate cancer: take your partners or is the last dance for me?
• The purification and specificity of a lipase fromVernonia anthelmintica seed.
• Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
• Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
• Trench entrapment: is ketamine safe to use for sedation in head injury?
• Uterine innervation in fibroids: a qualitative study.